{
    "root": "308f3fae-8592-3ca6-e063-6394a90ac010",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Glimepiride",
    "value": "20250317",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "GLIMEPIRIDE",
            "code": "6KY687524K"
        }
    ],
    "indications": "Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see \n       \n \n  Clinical Studies (\n        \n  \n   14.1)\n       \n \n  ]. \n      \n\n \n                  \n                     Limitations of Use\n                  \n                  Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings.",
    "contraindications": "Recommended starting dose is 1 or 2 mg once daily. Increase in 1 or 2 mg increments no more frequently than every 1 to 2 weeks based on glycemic response. Maximum recommended dose is 8 mg once daily. ( 2.1 ) Administer with breakfast or first meal of the day. ( 2.1 ) Use 1 mg starting dose and titrate slowly in patients at increased risk for hypoglycemia (e.g., elderly, patients with renal impairment). ( 2.1 )",
    "warningsAndPrecautions": "Glimepiride tablets USP, are available in the following strengths and package sizes:  \n                  Glimepiride tablets USP, 2 mg are green, oval, flat beveled edged, uncoated tablets debossed “RDY” on one side and “321” separating “3” and “21” with bisect line scoring on the other side and are supplied in bottles of 30, 100, 500 and unit dose package of 100 (10 x 10).\n                  Unit of Use Bottles of 90:  2 mg (NDC 68645-572-90)                        \n                  Glimepiride tablets USP, 4 mg are blue, oval, flat beveled edged, uncoated tablets debossed “RDY” on one side and “322” separating “3” and “22” with bisect line scoring on the other side and are supplied in bottles of 30, 100, 500 and unit dose package of 100 (10 x 10).\n                  Unit of Use Bottles of 90:  4 mg (NDC 68645-573-90)                                    \n                  Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].\n                  Dispense in well-closed containers with safety closures.",
    "adverseReactions": "Glimepiride tablets are contraindicated in patients with a history of a hypersensitivity reaction to: \n                  \n                     Glimepiride or any of the product’s ingredients [see \n        \n  \n   Warnings and Precautions (\n         \n   \n    5.2)\n        \n  \n   ].\n       \n \n  \n                  \n                  \n                     Sulfonamide derivatives: Patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride. Do not use glimepiride in patients who have a history of an allergic reaction to sulfonamide derivatives."
}